Novel tool bypasses plasmid-based expression to increase stability and significantly reduce development time for a variety of synthetic biotechnology products
Dupixent peak sales ambition raised to more than €13 billion
Tardive dyskinesia (TD) is a movement disorder that is characterized by uncontrollable, abnormal and repetitive movements of the face, torso and/or other body parts, which may be disruptive and negatively impact patients
As a partner with IRIA, the company had a significant booth presence on-ground during the conference.
The funding will accelerate the AI-driven healthcare company's market expansion into the global market and support new product development
New collaboration will help customers reach sustainability goals for high-performance Udel PSU polymers in demanding applications.
Vela Analytics can create concise, evidence-based in-house reports that help customers with the information to make timely, informed decisions about possible treatment options
It celebrated its 100th session as LPC-100 in association with Mundial Pharma
Under the agreement, Technology Development Board and Bharat Biotech have pledged the support of Rs.200 crore each to create a continuous corpus of Rs.400 crores for the project
In May 2021, Daiichi Sankyo had submitted a supplemental new drug application (sNDA) for Tarlige tablets based on results from a phase 3 trial in patients with CNP
Subscribe To Our Newsletter & Stay Updated
